Lack of p16/CDKN2 alterations in thyroid carcinomas
- 19 March 1996
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 101 (1), 85-92
- https://doi.org/10.1016/0304-3835(96)04117-1
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Cancer Research UK (07670257)
This publication has 17 references indexed in Scilit:
- Rates of p16 ( MTS1 ) Mutations in Primary Tumors with 9p LossScience, 1994
- P16 gene in uncultured tumoursNature, 1994
- A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor TypesScience, 1994
- Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancersNature, 1994
- p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.Genes & Development, 1994
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993
- Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.Journal of Clinical Investigation, 1993
- p53 Mutations in Human CancersScience, 1991
- The p53 tumour suppressor geneNature, 1991
- Mutations in the p53 gene occur in diverse human tumour typesNature, 1989